Most adenocarcinomas express altered MUC1 as a tumour-associated antigen. Due to suboptimal glycosylation in tumour-associated MUC1, the apomucin core is exposed, revealing new epitopes for antibody-directed immunotherapy. The human PH1 Fab binds specifically to this MUC1 apomucin. We describe the engineering and functional characterization of bi-and trivalent recombinant antibody derivatives from the PH1 Fab. Biand tribodies were made using the disulfide-stabilized Fab fragment as a heterodimerization scaffold with PH1 single-chain variable fragments fused to either one or both Fab-chain C-termini. Immunoassays revealed 27-and 165-fold improved dissociation constants (K D 5 30 and 5 nM) of the PH1 bi-and tribodies compared with the parental Fab (K D 5 820 nM). Unexpectedly, major differences were seen in the ability of the antibody constructs to bind shed and tumour cell-tethered MUC1. While the tribody did not discriminate between both MUC1 forms, the bibody demonstrated preferential interaction with membrane-bound MUC1 compared with shed MUC1. This preferential recognition of membrane-bound MUC1, along with the high serum stability of the bibody, its intermediate size and efficient internalization by MUC1 1 cells, makes the human PH1-derived bibody a valuable candidate as a cancer-targeting therapeutic.
Introduction
Tumour-associated antigens (TAAs) are overexpressed or modified molecules found on the surface of tumour cells and constitute targets for therapeutic purposes. MUC1-TAA is a promising TAA present on a large number of adenocarcinomas. In its normal form, MUC1 is a highly glycosylated type I transmembrane protein containing a variable number of tandem repeats of 20 amino acids. Normal MUC1 is expressed on the luminal side of respiratory, gastrointestinal and urogenital epithelia (Andrianifahanana et al., 2006) . The MUC1-TAA differs from normal MUC1 in its overexpression, lower degree of glycosylation and loss of polarized expression. MUC1 is particularly overexpressed in cancers of the breast, ovaries, bladder and pancreas (Hollingsworth and Swanson, 2004) . In addition, overexpressed MUC1 inhibits E-cadherin-mediated cell -cell contact, thus promoting metastasis (Wesseling et al., 1996) . The lower degree of glycosylation leaves the protein core of the MUC1-TAA exposed, enabling discrimination by the immune system between normal and tumour-associated MUC1. Recently, several clinical trials using MUC1 core peptides as tumour vaccines yielded promising results (North and Butts, 2005; Yamamoto et al., 2005; Wierecky et al., 2006) . Complementary to this active immunotherapy approach, antibodies against MUC1 have been used for the treatment of bladder cancer (Malamitsi et al., 1995; Hughes et al., 2000) , non-small cell lung cancer (Pavlovic et al., 1993; Garkavij et al., 2005) and other aggressive malignancies such as pancreas carcinomas (Gold et al., 2007) . Although in some cases partial responses to treatment were observed (DeNardo et al., 1997) , the presence of shed MUC1 in serum was identified as an important factor in reducing the efficacy of anti-MUC1-TAA monoclonal antibody (MoAb) therapy (Davies et al., 1997) .
These and other studies also revealed more generic limitations inherent to the use of full size, often heterologous antibodies for the treatment of solid cancers. Thus, the rapid development of a human anti-mouse immune response (HAMA) against therapeutic murine antibodies strongly reduced the long-term efficacy of the treatment (DeNardo et al., 1997; Jankowitz et al., 2008) . The development of HAMA responses has been addressed by humanizing the constant regions of the antibody, such as in the huHMFG1 MoAb (Verhoeyen et al., 1993) , or by using phage displayderived human antibodies, such as the PH1 Fab-derived MoAb (Henderikx et al., 2002) .
Although full-sized MoAbs have brought major clinical benefits to patients, there are numerous indications that these 150 kDa molecules penetrate large, solid tumours less effectively than smaller molecules (Jain, 1990; Reilly et al., 1995; Wong et al., 2004; Jain et al., 2005; Leyton et al., 2008) . Antibody derivatives with a reduced size but with the same binding properties as MoAbs penetrate more readily into the tumour, which could result in improved clinical responses.
Recently, patient trials were performed in which an 80 kDa (Wong et al., 2004) . Although molecules ,60 kDa penetrate tissues even more readily because of the rapid clearance from the blood by the kidneys, these constructs are better suited for diagnostic purposes rather than therapeutic purposes Wu et al., 1996; Adams et al., 1998a,b; Viti et al., 1999) . Furthermore, monovalency of fragments reduces their functional-binding affinity and hence their capacity to accumulate at the tumour site before being flushed away from the bloodstream (Adams et al., 1998a, b) . Several groups indeed demonstrated an increased tumour localization by increasing the valency of recombinant antibody fragments from monovalent to bi-or trivalent (Nielsen et al., 2000; Zhou, 2003) . However, few authors have suggested efficient means for combining multivalency with a size acceptable for efficient tumour penetration (Iliades et al., 1997; Somasundaram et al., 1999; Wang et al., 2004) . Using the disulphide stabilized Fab fragment as a scaffold for heterodimerization, we previously showed that multivalent antibody derivatives of intermediate size (75 -100 kDa) are efficiently produced in mammalian expression systems (Schoonjans et al., 2000) . In this study, we describe the construction of human-like bi-and trivalent anti-MUC1 molecules, using the human PH1 anti-MUC1 Fab as a basic element in conjunction with the derived single-chain variable fragment (scFv). The suitability of the antibody derivatives for immunotherapy of cancer was evaluated by determining the stability in serum of the anti-MUC1 molecules, their internalization by MUC1 þ cell lines and the capacity of the PH1 Fab, bibody and tribody to differentiate between cellbound and shed MUC1-TAA.
Materials and methods

MUC1 antigen and antibodies
As a target for in vitro MUC1-TAA-binding studies, the PDTRPAPGS peptide from the MUC1 core was C-terminally fused to a mutant GroEL (mGroEL, AA 193-335 from Escherichia coli GroEL) and cloned into the pLT32H vector, including a N-terminal (His) 6 sequence. This molecule is efficiently produced in E.coli and purified with immobilized metal affinity chromatography (IMAC) (unpublished data). The human PH1 Fab (with k light chain) (Henderikx et al., 2002) and its derived scFv are specific for the PAP(GS) epitope and were a generous gift from H. Hoogenboom (Dyax, Luik, BE). Other anti-MUC1 MoAbs were Ma552 mouse IgG1 (Menarini, Zaventem, BE) specific for the TRPAPG epitope and HMPV (Becton Dickinson, Erembodegem, BE), which binds to APDTR.
Cell lines
All cell lines are of human origin. HEK293T, an embryonic kidney cell line containing the SV40 large T-antigen (SV40T tsA1609 ), was used for transient eukaryotic expression and was grown in Dulbecco's modified Eagle medium (DMEM) medium with standard supplements (DuBridge et al., 1987) . OVCAR-3 (a kind gift from Paula Henderikx, Dyax, BE) and SKOV-3 originated from ovarian adenocarcinomas, BT-20, SK-BR-3 and MDA-MB-231 from breast carcinomas, Capan-1 and Capan-2 from pancreatic adenocarcinomas, A549 from lung carcinoma, HT-29 and LoVo from colon carcinomas, Hela from cervix carcinoma, Colo16 from squamous cell carcinoma, HT-1080 from fibrosarcoma, C32 and A2058 from melanomas and K562 cells from a chronic myelogenous leukaemia. Cell lines were cultured in standard media with supplements according to American Type Culture Collection recommendations.
Plasmids and gene assembly
PH1 expression plasmids were constructed using the pCDNA3, pCDNA3.1zeo-(Invitrogen, Merelbeke, BE) and pCAGGS (Niwa et al., 1991) vectors for eukaryotic expression. Restriction enzymes, DNA-modifying enzymes and DNA polymerase were used as recommended by the manufacturers. DNA amplification was performed with Vent-DNA polymerase (New England Biolabs, Beverly, MA). Gene assembly was conducted by introduction of suitable restriction sites using modifying PCR primers. All PCR-derived fragments were sequence verified after cloning.
Construction of the trivalent anti-MUC1 tribody expression vectors
We first recloned the heavy and light chain of the PH1 Fab into the pES31 mammalian expression vector. The Fd fragment was amplified by PCR with primers NM265 (5 0 CAG GTCCAGCTGGTGCAGTC3 0 ) and NM263 (5 0 TATGGAT CCTTATCCGGAGGGCCCTGCGGCCGCACAAGATTTGG GCTC3 0 ). The resulting fragment was cut with BspEI and phosphorylated on the 5 0 terminus with T4-kinase (Promega, Leiden, NL) before being introduced into the pES31Hneo vector. The L chain was cloned in pES31 in a similar fashion using primers NM266 (5 0 CTTGAAATTGTGCTGAC TCAGTCTCC3 0 ) and NM264 (5 0 TATGGATCCTTATCCG GAGGGCCCACACTCTCCCCTGTTGAAGCTC3 0 ). For the construction of the bi-and tribody, the PH1 Fab was used as a heterodimerization scaffold as described before (Schoonjans et al., 2000) . Briefly, the DNA fragment coding for the flexible EPSGP(G 4 S) 3 linker was joined to the 3 0 end of the PH1 Fd gene with a ApaI/PvuI digest. In the same manner, the DVDGGSRGDGPG linker was joined to the 3 0 end of the PH1-L chain. Next, the PH1 scFv gene was amplified using PCR with primers NM 302 (5 0 AGCCCCGG GCAGGTCCAGCTGGTGCAGTC3 0 ) and NM 303 (5 0 TATG GATCCTTATCCGGATCGTTTGATATCCACTTTGGTC3 0 ). The fragment was phosphorylated on the 5 0 terminus with T4 kinase and introduced after the linker of the PH1-Fd chain by means of a BspeI digest. By using the BspEI site in the vector, the His 6 tag sequence was retained and thus joined to the C-terminus of the PH1 scFv. For cloning the PH1 scFv to the linker behind the PH1-L chain, we used a SmaI/ BamHI fragment. This was ligated to an Eco47III/PvuI fragment and a BamHI/PvuI fragment from pES31.
Production and purification of antibody fragments
For transient expression, HEK293T cells were transfected by Ca 3 (PO 4 ) 2 precipitation (O'Mahoney and Adams, 1994) . Cells were seeded at 4 Â 10 6 cells/175 cm 2 20 h before transfection; plasmid DNA (14 mg) was added to the cells, and 24 h later the cells were covered with supplemented DMEM containing 5 mg/l bovine insulin, 5 mg/l transferrin and 5 mg/l selenium (ITS). Medium was harvested every 48 h after transfection, centrifuged for 20 min at 13 000 g and filtered through 0.22 mm bottle-top filters (Nalgene, Neerijse, BE). Purification of the PH1 bibody and tribody was performed using cation-exchange chromatography, IMAC and gelfiltration as described previously (Willems et al., 2003) , generating .90% pure protein free of aggregates. We could obtain 3 mg pure bibody starting from 1150 ml supernatant and 1.5 mg pure tribody of 2400 ml supernatant.
Analysis of protein fractions
Protein fractions were TCA precipitated, separated by 10% SDS-PAGE and visualized using Coomassie Brilliant Blue dye or blotted to a nitrocellulose membrane. Immunodetection of blots was performed by incubating for 1 h consecutively with mouse IgG1 anti-human k serum, mouse IgG1 anti-human Fd serum (Sigma Aldrich, St. Louis, MO) and alkaline phosphatase conjugated anti-mouse IgG1 (BD Biosciences Pharmingen, SD, USA) in a solution containing 5% skimmed milk powder, 50 mM Tris pH 8.0, 0.47% NaCl, 0.2% NP40 and 0.02% NaN 3 . Subsequent visualization was carried out with Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-3 0 -Indolyphosphate p-Toluidine Salt substrate (NBT/BCIP, Roche,Vilvoorde, BE). Protein recovery and purity were determined on scanned Coomassie gels with Quantity One software (Bio-rad, Hercules, CA, USA). Protein concentrations of pure protein were measured with the Micro BCA TM Protein Assay Kit (Pierce, Rockford, IL) with IgG standard protein.
Production and purification of MUC1 from MUC1
þ cell supernatant
To obtain shed MUC1, OVCAR-3 cells were grown in roller bottles for 1 week. The cell supernatant was centrifuged for 20 min at 13 000 g and filtered over 0.22 mm bottle-top filters (Nalgene, Neerijse, BE). Anion exchange chromatography was performed. The pH of the sample was adjusted to pH 9.5 with 10 mM ethanolamine before loading on a 200 ml XK50/20 Q Sepharose Fast Flow (Amersham Biosciences, Uppsala, Sweden) column equilibrated with 10 mM ethanolamine buffer pH 9.5 and run at 9 ml/min. The column was eluted with an NaCl step gradient. The MUC1-containing fraction was concentrated and SEC was performed as described for the bi-and tribody purifications. Fractions from the void up to the 158 kDa molecular weight marker were pooled, as were all fractions running after this point. Protein samples were analysed on 7.5% SDS-PAGE gels. Western blots were developed through incubation with the anti-MUC1 Ma552 MoAb and alkaline phosphatase conjugated anti-mouse IgG1. From 2000 ml supernatant, 860 mg MUC1 with 85% purity was obtained.
Enzyme-linked immunosorbent assay
Maxisorb 96-well plates (Nunc Neerijse, Belgium) were coated overnight at room temperature with 50 ml mGroEL-MUC1 (10 mg/ml) in NaHCO 3 buffer pH 9.6. The plates were blocked with PBS buffer with 0.05% Tween 20 and 1% BSA (PBS -BSA) for 2 h at 378C. Triplicate dilution series of the antibody derivatives were added in 50 ml PBS -BSA and incubated for 1 h at 378C. In between steps, plates were washed three times with PBS þ 0.05% Tween 20. Detection was performed by incubating consecutively with mouse IgG1 anti-human k serum and alkaline phosphatase conjugated anti-mouse IgG1. After adding the p-nitrophenyl phosphate (PNPP) substrate in 10% diethanolamine þ 1 mM MgCl 2 pH 9.8, absorbance at 405 nm was measured in a microplate reader (Bio-Rad, Hercules, CA, USA). Experiments were performed twice and negative controls consisted of uncoated wells treated with antibodies and coated wells that received detection antibodies, but no samples. The coating of mGroEL-MUC1 Ag carrying a His 6 tag was checked with an anti-His antibody. Binding curves were fitted to the experimental enzyme-linked immunosorbent assay (ELISA) data using Prism 3.0 software (Graphpad, San Diego, CA). From these binding curves, the K D were calculated. For shed MUC1 and cellular ELISA, the HMPV and Ma552 MoAbs were used as positive controls. Cellular ELISA was performed in a similar manner on OVACR3 cells grown in 96-well plates and fixed using a 60% acetone/40% PBS mixture for 5 min at room temperature.
Surface plasmon resonance
Affinity analysis was performed using a BIAcore 2000 (BIAcore, Uppsala, SE) with HEPES-buffered saline running buffer (10 mM HEPES with 0.15 M NaCl, 3.4 mM EDTA and 0.005% surfactant P20 at pH 7.4). mGroEL-MUC1 was immobilized on a CM5 chip in acetate buffer 50 mM ( pH 4,5). This resulted in 1800 RU mGroEL-MUC1 coated on the chip. A second channel on the same chip was coated with a similar amount of BSA, which served as a negative control. The PH1 antibody derivatives were used as analytes in seven different concentrations, ranging from 12.5 to 6000 nM, at a flow rate of 10 ml/min. Glycine -HCl 50 mM ( pH 2.0) was used for elution. The k d , k a , K D and K A values were calculated from the combined sensogram of all concentrations using BIAeval 3.0 software (BIAcore, Uppsala, SE).
Flow cytometry
Aliquots of 2 Â 10 5 cells were labelled with PH1 derivatives in PBS containing 0.5% BSA and 0.02% NaN 3 (PBS-A) on ice for 2 h. After washing, the cells were allowed to subsequently interact with mouse IgG1 anti-human k and Alexa Fluor 488-conjugated goat anti-mouse antibodies (Invitrogen, Merelbeke, BE) on ice for 1 h. The cells were suspended to a final concentration of 666 cells/ml. For isotype control, 10 nM 9E10 MoAb (mouse IgG1) was used instead of PH1 derivatives. No significant binding was detected with 9E10. Flow cytometric analysis was performed using an FACScan flow cytometer (BD, Erembodegem, BE). Data analysis based on the collection of 10 000 events per sample was performed using WinMDI 3.7 software (Joseph Trotter).
Internalization and confocal microscopy
OVCAR-3 cells were grown in 8-well chamber slides (Lab-Tek Chamber CVG, Nunc) and were incubated with PH1 derivatives in 200 ml of medium for various time periods under saturating conditions. For the bibody and tribody this was 20 mg/ml. Because of the low affinity of the Fab, the cells were incubated with 100 mg/ml. Cells were washed with PBS and fixed for 5 min at room temperature with a 60% acetone/40% PBS mixture. After a PBS wash, wells were blocked with PBS -BSA. PH1 molecules were detected by incubation with mouse anti-human k IgG1 and Alexa-fluor-488 labelled goat anti-mouse antibody for 1 h at 378C. RNAse was added to remove cytosolic RNA. The cells were mounted in 50 mM Tris pH 8 þ 80% glycerol. Nuclei were stained with propidium iodide. Confocal images were Anti-MUC1 bi-and tribodies acquired with an Leica TCS SP5 AOBS laser scanning inverted DMi6000 microscope, equipped with 40Â and 63Â HCX plan Apo oil objectives and controlled by the LAS-AF software platform (Leica Microsystems, Wetzlar, Germany). ImageJ 1.3 (Rasband W.S., NIH, Bethesda, Maryland) was used for generating image overlays and CorelPhotopaintX4 (Corel, Ottawa, Canada) was used for cropping and brightness adjustment of the final images.
Results
Construction and expression of the anti-MUC1 bi-and tribody
We previously reported the creation of bi-and tribodies based on the highly efficient heterodimerization of Fd and L chains in mammalian cells (Schoonjans et al., 2000) . By joining scFv fragments to the C-terminus of the Fd or L chains of a Fab fragment, bispecific or bivalent bibodies of +75 kDa are generated. Adding a scFv to the other Fab chain then leads to trispecific, bispecific bivalent or trivalent tribodies (+100 kDa) (Fig. 1A) . In this study, the Fab-scFv template was used in a three-step process to create humanlike bivalent and trivalent molecules with affinity for the MUC1-TAA. First, both the Fd-and the kL-chain gene segments coding for the human PH1 Fab fragment specific for the PAP(GS) epitope on MUC1 were integrated into the pES31 mammalian expression vector and co-expressed in HEK293T cells, producing the 50 kDa PH1 Fab. In the second step, a plasmid was designed, coding for PH1 Fd fragment to which the PH1 scFv and His 6 tag were joined to the C-terminus with a flexible linker (Fig. 1B) . Co-expression in HEK293T cells of the PH1 Fab light chain vector yielded a bivalent PH1 bibody of 77 kDa. Thirdly, a vector was constructed with the PH1 scFv joined with a flexible linker to the PH1 kL-chain C-terminus. When both PH1-scFv vectors were co-expressed, this resulted in the production of a 104 kDa trivalent anti-MUC1-TAA tribody. The heterodimeric nature of the Fab, bibody and tribody was confirmed by western blot detection with human k and g specific antibodies (Fig. 1C) . The PH1 Fab, bi-and tribody were then purified from HEK293T cell culture supernatants using their C-terminal His 6 tag as described by Schoonjans et al. (2000) . The recombinant proteins, estimated to be over 90% pure, showed good solubility and did not aggregate (not shown).
Avidity for immobilized MUC1 peptide
The binding characteristics of the bivalent and trivalent PH1 derivatives were compared with the parent PH1 Fab using ELISA (Fig. 2) . The mGroEL-MUC1 peptide, consisting of the PDTRPAPGS peptide from MUC1 C-terminally fused to AA 193 -335 from E.coli GroEL, was immobilized on ELISA plates. Serial dilutions of the monovalent PH1 Fab, bivalent PH1 bibody and trivalent PH1 tribody were allowed to interact with the peptide antigen. The PH1 trivalent tribody showed an estimated K D of 20 + 1 nM. This is 65-fold higher than observed for the Fab fragment (K D ¼ 1300 + 40 nM) and 3-fold higher than for the PH1 bibody (K D ¼ 63 + 2 nM). No binding to normal untagged mGroEL was observed. A more accurate measurement of the binding characteristics was obtained by surface plasmon resonance analysis (Table S1 in Supplementary data.). The resulting K D of 5 nM for the PH1 tribody, 30 nM for the PH1 bibody and 820 nM for the PH1 Fab are slightly lower than the estimated K D from ELISA, but confirm the general differences in affinity observed between the respective antibody derivatives. Clearly, increasing the valency of the monovalent PH1 Fab to a bivalent bibody or trivalent tribody significantly improves the functional affinity of the Fab.
Improved binding on MUC1
þ cells of PH1 bi-and tribodies
To determine the PH1 Fab and bi-and tribody cell-binding characteristics, we first examined by flow cytometry the expression levels of the MUC1 epitope on 17 human cancer cell lines using the PH1 tribody. K562, HEK293T, Colo16, MDA-MB-231, Hela, BT-20 and A2058 showed no to very little interaction with 200 nM PH1 tribody (see Supplementary data.). Significant binding was observed for HT1080, Lovo, SKOV3, C32, A549, HT29, SKBR-3, Capan-1, Capan-2 and OVCAR-3 cells in order of increasing intensity (Fig. 3A) . On this basis, OVCAR-3 cells were selected for further analysis of the PH1 Fab, bi-and tribodybinding characteristics. Staining of fixed OVCAR-3 cells with serial dilutions (1 -2000 nM) of the respective antibody derivatives (Fig. 3B) Binding avidity for tumour cell shed MUC1
Most MUC1 þ cells not only express MUC1 on the membrane, but also shed significant quantities of the molecule. To verify binding to the shed form of the MUC1-TAA, shed MUC1 was purified from the culture supernatant of OVCAR-3 cells using anion exchange and size-exclusion chromatography. Analysis on SDS-PAGE gels showed the purity of the MUC1 to be +85% (Fig. 4A and Supplementary data.). The identity of the shed MUC1 was further confirmed by ELISA using the MUC1-specific MoAbs, Ma552 and HMPV, for detection (Fig. 4B) . When assaying the PH1 Fab, bibody and tribody, marked differences in their binding to shed MUC1 were observed (Fig. 4C ). The monovalent Fab showed an extremely low affinity with a K D ¼ 4900 + 3600 nM, about eight times higher than the value observed with cell-bound MUC1. Also the PH1 bibody showed a decreased affinity for shed MUC1 compared with peptide or cell-bound MUC1, with a K D of 110 + 10 nM, four times higher than the K D measured for MUC1 on OVCAR-3 cells. In contrast, the PH1 tribody showed no difference in avidity for both MUC1 forms, having a K D of 7 + 1 nM for the shed MUC1, identical to the K D for membrane-bound MUC1. As a consequence of this differential avidity, the PH1 Fab and its bibody derivative, but not the tribody, may be considered as discriminatory between membrane-bound and shed forms of MUC1.
Internalization
The rate at which the PH1 molecules were internalized and processed by MUC1 þ cells was determined on cultured OVCAR-3 cells. After 1, 2, 4 and 6 h of culture with the Fig. 2 . Binding characteristics of PH1 derivatives to mGroEL-MUC1 peptide. Increasing concentrations of PH1 Fab (closed diamonds), bibody (closed circles) and tribody (closed triangles) were allowed to interact with mGroEL-MUC1 immobilized onto a microwell plate. After 405 nm OD readout, saturation-binding curves and constants were calculated using non-linear regression. Mean + SEM of triplicates is shown. Anti-MUC1 bi-and tribodies individual antibody derivatives, the cells were fixed, permeabilized and stained to reveal the presence of PH1 by confocal microscopy analysis (Fig. 5) . Rapid internalisation of all PH1 molecules was visible already after 1 h of co-culture. After 2 h, the amounts of PH1 molecules detectable at the cell membrane and within the cells were low, and after 4 h only marginal traces of antibody could be detected. This demonstrates that following initial binding by the PH1 molecules, the majority of MUC1 molecules are rapidly processed by the OVCAR-3 cells.
Functional stability in mouse serum
Longevity in serum is an important parameter when using engineered antibody fragments in vivo. To determine how long the PH1 derivatives remain active in serum, samples were incubated at 378C for increasing time intervals (0, 1, 3, 5, 24, or 48 h) in mouse serum or PBS followed by an ELISA analysis (Fig. 6) . In PBS, no apparent decrease in activity was observed; the products remained stable at 48C for several months (not shown). In mouse serum, a gradual decrease in activity was observed for all three anti-MUC1-TAA constructs. At 48 h, both the Fab and tribody retained 78% of their initial functionality. The bibody showed a lower decay rate with 88% functional bibody remaining after 48 h.
Discussion
The overexpressed and under-glycosylated form of MUC1 is associated with poor prognosis in several cancers, making it an interesting target for antibody therapy (Fujita et al., 1999; Tamada et al., 2002; Hinoda et al., 2003; Garbar et al., 2008) . In MUC1 þ malignancies, large quantities of MUC1 can however also be shed in the serum (Hayes et al., 1986) , thus reducing the efficacy of the treatment by sequestering anti-MUC1 antibodies before they reach their tumour target (Davies et al., 1997; Rubinstein et al., 2006) . Despite possible problems with shed MUC1, the presence of repeated epitopes on a single MUC1 molecule still makes this an interesting TAA for multivalent binding antibody derivatives.
We verified to what extent multivalent antibody derivatives, based on the human PH1 Fab and containing one (bivalent bibody) or two (trivalent tribody) PH1 scFvs, differentially bind to the core MUC1 peptide and the cell-bound and shed forms of the TAA. Having sizes of 77 and 104 kDa, respectively, these antibody derivatives have the advantage of being smaller than full-size MoAbs and therefore penetrate better into the tumour. Compared with the smaller scFv and Fab fragments, the bi-and tribody formats have the additional advantage of a slower renal clearance.
Immunoassays with MUC1 minimal peptide antigen revealed the higher avidity of the PH1 tribody for MUC1, compared with the bibody and Fab. This increase in avidity also brings the PH1 bibody and tribody in the optimum range of affinity (K D 100 nM), effective for tumour targeting (McCall et al., 2001; Leyton et al., 2008) . In contrast, the small and low affinity PH1 Fab (K D ¼ 600 nM) appears to be unsuited for use in anti-tumour therapy.
On MUC1 þ cells from pancreas and ovarian carcinoma cell lines, the PH1 tribody consistently showed the highest reactivity (not shown), in line with the high avidity of the tribody, which is comparable to the PH1 IgG1 construct made from the PH1 Fab by Henderikx et al. (2002;  K D ¼ 9 nM and K D ¼ 8.7 nM respectively). Cellular ELISA using the MUC1 þ OVCAR-3 cell line confirmed the mutual differences in avidity between the PH1 bibody and tribody as observed with purified peptide antigen. However, when assaying shed MUC1 purified from OVCAR-3 cells, the mutual differences in apparent affinity were strongly incremented. The bibody showed a four times lower avidity for the shed form of MUC1 compared with membrane-bound MUC1, whilst the tribody showed no difference in apparent affinity. Also, the repetitive nature of the targeted MUC1 epitope implies that this multivalent binding of a targeting molecule should still hold true for MUC1 present in the serum. These results identify the bibody as an ideal candidate for distinguishing the cell-bound TAA from its shed counterpart. This pronounced difference in avidity for either MUC1 form may be due to the structure of the shed MUC1. Following expression on the plasma membrane, MUC1 is reinternalized and undergoes further glycosylation. This process is repeated several times before the MUC1 molecule is cleaved from the cell surface and shed into the surroundings (Litvinov and Hilkens, 1993; Engelmann et al., 2005) . As a consequence, shed MUC1 is more likely to have additional glycosylated sites that shield the PH1 peptide epitope. The tribody, having a statistically larger chance than the bibody to 'find' and bind to the few free epitopes on the more glycosylated-shed MUC1 may as a consequence retain its avidity to secreted MUC1 while the bibody does not. Such hypothesis may very well explain the observed differential binding patterns to shed and cell-bound MUC1 of the PH1 bi-and tribody. The PH1 bi-and tribody remain stable in mouse serum. Differences in serum stability between bibody and tribody could be due to slightly higher protease sensitivity of the latter. Both bibody and tribody show rapid internalization in their target cells, reflecting the recycling of MUC1 on the plasma membrane (Litvinov and Hilkens, 1993) . This rapid internalization has been observed for several anti-MUC1 antibodies (Pietersz et al., 1997; Pericleous et al., 2005) . Rendering the MUC1-TAA less suitable for imaging and active immune therapy, this rapid internalization, however, makes the molecules well suited for cytotoxin or radionuclide delivery. Moreover, with larger payloads, the smaller bibody has the additional advantage of keeping the size of the complex in the 60-120 kDa range, which is considered optimal for an efficient biodistribution of the molecule. Recently, a humanized anti-PSCA minibody of affinity similar to that of the PH1 bibody (K D ¼ 46 nM) demonstrated excellent tumour-targeting abilities in a prostate cancer xenograft model (Leyton et al., 2008) . Therefore, the affinity of the PH1 bibody should also be suitable for tumour targeting.
In summary, this paper describes the construction and binding characteristics to shed and tumour cell-associated MUC1 of human monovalent, bivalent and trivalent antibody derivatives. While the monovalent PH1 Fab efficiently discerned shed MUC1 from cell-bound MUC1, its poor affinity makes it unsuitable as a therapeutic agent. In contrast, the tribody showed a 65-fold increased avidity for MUC1, but did not discriminate between shed and cell-bound MUC1. Also the bibody showed an increased avidity and discriminated between cell-bound and shed MUC1; binding to cell MUC1 was 4-fold stronger. Along with the intermediate (77 kDa) size of the Fab-scFv molecule, this preferential recognition of tumour cell-bound MUC1 makes the bibody an ideal candidate for anti-MUC1 cancer therapy. . Stability in serum of the PH1 Fab, bibody and tribody. PH1 samples were incubated at 378C for increasing time intervals in the mouse serum. The remaining amount of functional Fab (closed diamonds), bibody (closed circles) and tribody (closed triangles) was gauged by an ELISA assay and is presented as percent of initial-binding capacity. Mean + SEM of triplicates is shown.
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